<DOC>
	<DOCNO>NCT02932878</DOCNO>
	<brief_summary>An Open Label , Safety Study Assess Potential Adrenal Suppression Following Treatment DSXS ( Taro Pharmaceuticals U.S.A. , Inc. ) Patients Plaque Psoriasis</brief_summary>
	<brief_title>An Open Label , Safety Study Assess Potential Adrenal Suppression</brief_title>
	<detailed_description>To evaluate potential DSXS suppress HPA axis function patient mild moderate plaque psoriasis . To evaluate efficacy parameter adverse event ( AE ) profile DSXS administer patient mild moderate plaque psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male non pregnant , non lactate female Patients 2 year age</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>